GSK Receives Offer for its Thrombosis Brands and Related Manufacturing Site - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

GSK Receives Offer for its Thrombosis Brands and Related Manufacturing Site
A proposed deal with Aspen includes GSK’s site in Notre-Dame-de-Bondeville, France.


GlaxoSmithKline (GSK) has received an offer for its thrombosis brands and related manufacturing site in Notre-Dame de Bondeville (NDB), France from Aspen Global and Aspen Pharmacare Holdings.

The financial terms are confidential at this time, but the offer includes the transfer of GSK’s Arixtra (fondaparinux sodium) and Fraxiparine (nadroparin calcium injection) brands to Aspen, excluding to China, India, and Pakistan, along with the NDB manufacturing site and the majority of employees at NDB and certain dedicated commercial employees.

Aspen and GSK have agreed to a period of exclusivity to consider the offer, which is subject to consultation with employees and the relevant works councils, according to a GSK press statement. The proposed transaction is aligned to GSK’s strategy of focusing on products with the most growth potential and the delivery of its pipeline.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality

Click here